IGLV1 40 | ENSG00000211653 | NCBI 28825

Details for: IGLV1 40

Associated with

Adaptive immune system
(R-HSA-1280218)
Anti-inflammatory response favouring leishmania parasite infection
(R-HSA-9662851)
Antigen activates b cell receptor (bcr) leading to generation of second messengers
(R-HSA-983695)
Binding and uptake of ligands by scavenger receptors
(R-HSA-2173782)
Cd22 mediated bcr regulation
(R-HSA-5690714)
Cell surface interactions at the vascular wall
(R-HSA-202733)
Classical antibody-mediated complement activation
(R-HSA-173623)
Complement cascade
(R-HSA-166658)
Creation of c4 and c2 activators
(R-HSA-166786)
Disease
(R-HSA-1643685)
Fc epsilon receptor (fceri) signaling
(R-HSA-2454202)
Fceri mediated ca+2 mobilization
(R-HSA-2871809)
Fceri mediated mapk activation
(R-HSA-2871796)
Fceri mediated nf-kb activation
(R-HSA-2871837)
Fcgamma receptor (fcgr) dependent phagocytosis
(R-HSA-2029480)
Fcgr3a-mediated il10 synthesis
(R-HSA-9664323)
Fcgr3a-mediated phagocytosis
(R-HSA-9664422)
Fcgr activation
(R-HSA-2029481)
Hemostasis
(R-HSA-109582)
Immune system
(R-HSA-168256)
Immunoregulatory interactions between a lymphoid and a non-lymphoid cell
(R-HSA-198933)
Infectious disease
(R-HSA-5663205)
Initial triggering of complement
(R-HSA-166663)
Innate immune system
(R-HSA-168249)
Leishmania infection
(R-HSA-9658195)
Leishmania parasite growth and survival
(R-HSA-9664433)
Leishmania phagocytosis
(R-HSA-9664417)
Parasite infection
(R-HSA-9664407)
Parasitic infection pathways
(R-HSA-9824443)
Potential therapeutics for sars
(R-HSA-9679191)
Regulation of actin dynamics for phagocytic cup formation
(R-HSA-2029482)
Regulation of complement cascade
(R-HSA-977606)
Role of lat2/ntal/lab on calcium mobilization
(R-HSA-2730905)
Role of phospholipids in phagocytosis
(R-HSA-2029485)
Sars-cov infections
(R-HSA-9679506)
Scavenging of heme from plasma
(R-HSA-2168880)
Signaling by the b cell receptor (bcr)
(R-HSA-983705)
Vesicle-mediated transport
(R-HSA-5653656)
Viral infection pathways
(R-HSA-9824446)
Adaptive immune response
(GO:0002250)
Antigen binding
(GO:0003823)
Extracellular region
(GO:0005576)
Immune response
(GO:0006955)
Immunoglobulin complex
(GO:0019814)
Plasma membrane
(GO:0005886)

Significant Cells

Cell Significance Index (CSI) scores for the chosen context(s)

class switched memory B cell CL0000972

CSI 25.69

rCSI 19.18%

PRS 99.41
IgA plasma cell CL0000987

CSI 11.09

rCSI 11.35%

PRS 97.71
immature B cell CL0000816

CSI 10.09

rCSI 7.49%

PRS 99.68
IgG plasma cell CL0000985

CSI 9.56

rCSI 11.45%

PRS 98.68
natural killer cell CL0000623

CSI 8.86

rCSI 17.18%

PRS 98.03
CD4-positive, alpha-beta T cell CL0000624

CSI 6.39

rCSI 8.18%

PRS 97.05
innate lymphoid cell CL0001065

CSI 5.94

rCSI 12.26%

PRS 96.47
plasmablast CL0000980

CSI 5.3

rCSI 4.17%

PRS 98.74
small pre-B-II cell CL0000954

CSI 5.2

rCSI 5%

PRS 99.46
basal cell of epidermis CL0002187

CSI 5.07

rCSI 8.99%

PRS 88.19
intestine goblet cell CL0019031

CSI 4.14

rCSI 3.67%

PRS 98.82
suprabasal keratinocyte CL4033013

CSI 3.17

rCSI 5.17%

PRS 90.19
CD8-positive, alpha-beta memory T cell, CD45RO-positive CL0001203

CSI 2.55

rCSI 3.09%

PRS 91.4
glial cell CL0000125

CSI 1.44

rCSI 5.47%

PRS 97.26

Cell ID: Standard Cell Ontology term used for mapping and comparing cells across experiments. Ensures consistency in analyzing cellular functions across tissues.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this specific cell.

Network Configuration

Explore relationships of the current gene. Select an Interaction Source: 'ONTOLOGY' for shared pathways (GO/Reactome) or 'STRING' for protein-protein interactions. Further refine by selecting context genes and comparing Cell Significance Index (CSI) scores between baseline and target cell types and their specific contexts.

Context Genes (max 20):

Interaction Source:

Pathway Categories (for ONTOLOGY source):

Baseline Cell Type:

Baseline Cell Context(s): Comma-separated if multiple.

Target Cell Type:

Target Cell Context(s): Comma-separated if multiple.

Legend:

Query Gene
Node Color (Target Cell CSI, relative to current network):
- Very High
- High
- Medium
- Low
- Very Low
- CSI N/A
Node Size: Proportional to Target Cell CSI magnitude
STRING PPI Edge
Shared Pathway Edge (ONTOLOGY)

Loading network (please wait)...

Other Information

This section provides additional information about the gene, including a description generated by an AI language model and details about associated proteins.

Description

## Summary [IGLV1 40](/details-gene/28825) is a gene that encodes the variable (V) segment of an immunoglobulin lambda light chain. As a fundamental component of the adaptive immune system, it contributes to the vast diversity of antigen-binding sites on antibodies. Its expression is overwhelmingly associated with the B-cell lineage, with the highest significance observed in [class switched memory B cell](/details-cell/CL0000972), various [plasma cells](/details-cell/CL0000786), and developing [B cells](/details-cell/CL0000236). Functionally, [IGLV1 40](/details-gene/28825) is integral to [antigen binding](/details-ontology/GO0003823) and the formation of the [immunoglobulin complex](/details-ontology/GO0019814), playing a critical role in humoral immunity and the response to pathogens. ## Cellular Roles and Expression Landscape The expression profile of [IGLV1 40](/details-gene/28825) firmly establishes its identity as a key gene in the humoral adaptive immune system. **Overall**, its most significant expression is found in cell types central to antibody production. * **B-Cell Lineage Dominance:** The gene shows the highest significance in [class switched memory B cell](/details-cell/CL0000972) (CSI: 25.69), followed by terminally differentiated antibody-secreting cells such as [IgA plasma cell](/details-cell/CL0000987) (CSI: 11.09) and [IgG plasma cell](/details-cell/CL0000985) (CSI: 9.56). High significance is also noted in earlier developmental stages, including [immature B cell](/details-cell/CL0000816) (CSI: 10.09) and [plasmablast](/details-cell/CL0000980) (CSI: 5.30), underscoring its involvement throughout B-cell maturation and effector function. * **Broader Lymphoid Association:** Beyond the B-cell lineage, [IGLV1 40](/details-gene/28825) demonstrates relevance in other lymphoid populations, including [natural killer cell](/details-cell/CL0000623) (CSI: 8.86), [CD4-positive, alpha-beta T cell](/details-cell/CL0000624) (CSI: 6.39), and [innate lymphoid cell](/details-cell/CL0001065) (CSI: 5.94). This suggests either a potential role in these cells, such as surface immunoglobulin expression, or indicates close functional interactions with the B-cell compartment. * **Expression in Non-Immune Tissues:** Interestingly, the data indicate significant expression in several non-hematopoietic cell types, including [basal cell of epidermis](/details-cell/CL0002187) (CSI: 5.07), [intestine goblet cell](/details-cell/CL0019031) (CSI: 4.14), and [suprabasal keratinocyte](/details-cell/CL4033013) (CSI: 3.17). This pattern may reflect resident immune populations within these barrier tissues or could point towards a non-canonical function of this immunoglobulin gene segment in epithelial contexts. Minor significance is also noted in [glial cell](/details-cell/CL0000125) (CSI: 1.44). ## Pathways and Molecular Function The functional annotations for [IGLV1 40](/details-gene/28825) are highly consistent with its role as a constituent of antibodies. Its primary molecular function is defined as [antigen binding](/details-ontology/GO0003823), contributing to the biological process of the [adaptive immune response](/details-ontology/GO0002250). Reactome pathway analysis reveals its central position within the [adaptive immune system](/details-pathway/R-HSA-1280218). Its involvement is critical for [signaling by the B cell receptor (BCR)](/details-pathway/R-HSA-983705), the initial step in B-cell activation. Consequently, it is implicated in numerous downstream effector pathways that are mediated by antibodies, such as [classical antibody-mediated complement activation](/details-pathway/R-HSA-173623) and [Fcgamma receptor (FCGR) dependent phagocytosis](/details-pathway/R-HSA-2029480). This functional profile aligns perfectly with its high expression in [plasma cells](/details-cell/CL0000786) and memory [B cells](/details-cell/CL0000236), the primary mediators of these processes. Furthermore, the enrichment in pathways related to [Leishmania infection](/details-pathway/R-HSA-9658195) and [SARS-CoV infections](/details-pathway/R-HSA-9679506) highlights the direct role of antibodies incorporating this V-segment in the host defense against a range of pathogens. ## Research Directions The data presented provide a clear picture of [IGLV1 40](/details-gene/28825) as a core component of humoral immunity, but also raise intriguing questions about its potential roles beyond the classical B-cell lineage. ### Proposed Hypotheses: 1. **Preferential Selection in Memory Responses:** The exceptionally high CSI score in [class switched memory B cell](/details-cell/CL0000972) suggests that antibodies utilizing the [IGLV1 40](/details-gene/28825) segment may be preferentially selected during germinal center reactions due to favorable biophysical properties, leading to an enrichment in the long-lived humoral memory pool against certain classes of antigens. 2. **Non-Canonical Function in Epithelial Barrier Tissues:** The significant expression noted in [basal cell of epidermis](/details-cell/CL0002187) and [intestine goblet cell](/details-cell/CL0019031) may indicate a novel, non-canonical role for [IGLV1 40](/details-gene/28825) in epithelial cell biology, potentially related to innate immune sensing or maintenance of barrier integrity, independent of its function in a full antibody complex. ### Experimental Approach: To test the hypothesis of a non-canonical function in epithelial cells (Hypothesis 2), a combination of spatial transcriptomics and high-resolution immunofluorescence could be applied to human skin and intestinal biopsies. This would determine if [IGLV1 40](/details-gene/28825) transcripts and protein products co-localize specifically within epithelial cells (e.g., keratinocytes or goblet cells) rather than with tissue-infiltrating [B cells](/details-cell/CL0000236). Functional validation could be achieved through siRNA-mediated knockdown of [IGLV1 40](/details-gene/28825) in primary human keratinocyte or intestinal organoid cultures, followed by assays measuring changes in inflammatory cytokine secretion (e.g., via ELISA) or barrier function (e.g., via transepithelial electrical resistance). ### Therapeutic Potential: As a gene segment, [IGLV1 40](/details-gene/28825) itself is not a direct therapeutic target. However, the specific antibodies that utilize this segment are of high clinical relevance. If a population of pathogenic autoantibodies in an autoimmune disease or the B-cell receptor of a B-cell malignancy are found to be clonally restricted and preferentially use [IGLV1 40](/details-gene/28825), this segment could serve as a biomarker or a component of a therapeutic target. Strategies could include the development of anti-idiotype antibodies or CAR-T cells that recognize the unique antigen-binding region formed by [IGLV1 40](/details-gene/28825) in the context of a specific heavy chain, enabling highly targeted elimination of pathogenic B-cell clones.

Disclaimer: This in-silico analysis is generated by an AI language model and may contain inaccuracies or hallucinations. However, it is cross-referenced with curated gene expression data from major biological sources. Please verify the information before use.